SeaCrest Wealth Management LLC Invests $48,000 in Guardant Health, Inc. (NASDAQ:GH)

SeaCrest Wealth Management LLC bought a new position in shares of Guardant Health, Inc. (NASDAQ:GHGet Rating) in the 2nd quarter, Holdings Channel reports. The fund bought 1,200 shares of the company’s stock, valued at approximately $48,000.

Other hedge funds have also made changes to their positions in the company. HM Payson & Co. lifted its position in Guardant Health by 100.0% in the first quarter. HM Payson & Co. now owns 1,000 shares of the company’s stock valued at $66,000 after purchasing an additional 500 shares during the period. CWM LLC lifted its position in Guardant Health by 73.6% in the second quarter. CWM LLC now owns 1,734 shares of the company’s stock valued at $70,000 after purchasing an additional 735 shares during the period. Nelson Van Denburg & Campbell Wealth Management Group LLC acquired a new stake in Guardant Health in the first quarter valued at about $89,000. OneAscent Financial Services LLC acquired a new stake in Guardant Health in the second quarter valued at about $211,000. Finally, FDx Advisors Inc. lifted its position in Guardant Health by 18.0% in the second quarter. FDx Advisors Inc. now owns 5,376 shares of the company’s stock valued at $217,000 after purchasing an additional 821 shares during the period. Institutional investors and hedge funds own 89.36% of the company’s stock.

Analysts Set New Price Targets

GH has been the subject of a number of research reports. Credit Suisse Group reduced their price target on shares of Guardant Health from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Friday, November 4th. Craig Hallum initiated coverage on shares of Guardant Health in a research report on Wednesday, October 19th. They set a “buy” rating and a $88.00 price target for the company. Cowen reduced their price target on shares of Guardant Health from $110.00 to $83.00 in a research report on Friday, November 4th. Piper Sandler downgraded shares of Guardant Health from an “overweight” rating to a “neutral” rating and reduced their price target for the company from $65.00 to $50.00 in a research report on Tuesday, November 1st. Finally, JPMorgan Chase & Co. reduced their price target on shares of Guardant Health from $100.00 to $85.00 and set an “overweight” rating for the company in a research report on Friday. One investment analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Guardant Health presently has an average rating of “Moderate Buy” and an average price target of $99.60.

Insiders Place Their Bets

In other Guardant Health news, insider Kumud Kalia sold 3,125 shares of Guardant Health stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $51.87, for a total value of $162,093.75. Following the completion of the sale, the insider now directly owns 20,135 shares of the company’s stock, valued at approximately $1,044,402.45. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.90% of the stock is owned by corporate insiders.

Guardant Health Stock Down 0.5 %

GH stock opened at $48.17 on Monday. The stock has a market capitalization of $4.93 billion, a P/E ratio of -8.12 and a beta of 0.63. The company has a debt-to-equity ratio of 6.82, a quick ratio of 6.10 and a current ratio of 6.46. Guardant Health, Inc. has a one year low of $27.65 and a one year high of $111.48. The company has a 50 day moving average price of $50.85 and a two-hundred day moving average price of $47.06.

About Guardant Health

(Get Rating)

Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients.

Featured Stories

Want to see what other hedge funds are holding GH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Guardant Health, Inc. (NASDAQ:GHGet Rating).

Institutional Ownership by Quarter for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.